Status:
SUSPENDED
Study of Oral Palifosfamide Tris in Solid Tumors
Lead Sponsor:
Alaunos Therapeutics
Conditions:
Advanced Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The study of maximum tolerated dose and safety of oral palifosfamide tris capsules in advanced, refractory, solid tumors
Eligibility Criteria
Inclusion
- Subjects with histological or cytological confirmation of advanced cancer that is refractory to standard therapies for their condition.
- Men and women of ≥18 years of age.
- Life expectancy of at least 12 weeks.
- Eastern Cooperative Oncology Group (ECOG) performance score ≤2 (see Appendix 4).
- Eligible subjects MUST have at least one measurable lesion as defined by RECIST guidelines. If the measurable disease is restricted to a solitary lesion, its neoplastic nature should be confirmed by cytology/histology. Measurable lesions must NOT have been in a previously irradiated field or injected with biological agents.
- Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements, to be conducted ≤2 weeks prior to Baseline:
- Creatinine \< 1.5× upper limit of normal (ULN) OR a calculated creatinine clearance ≥70 cc/min
- Total bilirubin ≤2×ULN
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3×ULN
- Granulocytes in peripheral blood ≥2.0×109/L, hemoglobin ≥8.5 g/dL, and platelets ≥50,000/µL
- Written informed consent in compliance with ZIOPHARM policies and the Human Investigation Review Committee (IEC/IRB) having jurisdiction over the site.
- Men and women of childbearing potential must use effective contraception from Screening through his/her duration of study participation.
- Women of childbearing potential must have a negative serum pregnancy test prior to entering the study.
Exclusion
- New York Heart Association (NYHA) functional Class ≥III myocardial infarction (see Appendix 5) within 6 months.
- Uncontrolled cardiac arrhythmia other than asymptomatic atrial fibrillation; a QTc ≥450 msec; or a ≥Grade 2 atrioventricular (AV) block or left bundle branch block (LBBB); or documented history of prolonged QTc.
- Pregnancy and/or lactation.
- Uncontrolled systemic infection (documented with microbiological studies).
- Inadequate renal function as defined by the presence of one or more of the following:
- Creatinine clearance (CrCl) \<70 cc/min
- Serum creatinine \>1.5×ULN
- Prior nephrectomy
- Urinary tract obstruction
- Anticancer chemotherapy or immunotherapy during the study or within 4 weeks of study entry (mitomycin C or nitrosureas should not be given within 6 weeks of study entry).
- Radiotherapy during study or within 3 weeks of study entry.
- Surgery within 4 weeks of start of study drug.
- Other investigational drug therapy outside of this trial during or within 4 weeks of study entry.
- History of invasive second primary malignancy diagnosed within the previous 3 years except for Stage I endometrial/cervical carcinoma or prostate carcinoma treated surgically, and non-melanoma skin cancer.
- Substance abuse, medical, psychological, or social conditions that may interfere with the subject's participation in the study or evaluation of study results.
- Any condition that is unstable or could jeopardize the safety of the subject and his/her compliance in the study.
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2009
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00607711
Start Date
March 1 2008
End Date
November 1 2009
Last Update
May 5 2008
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.